Skip to main content
Fig. 1 | Journal of Molecular Medicine

Fig. 1

From: Somatic non-cancerous PIK3CA-related overgrowth syndrome treated with alpelisib in North America

Fig. 1

Clinical manifestations at baseline (a to g) and after 2 months on a PIK3CA inhibitor (H). (ad) External appearance. Left leg is seen to be moderately enlarged and right leg to harbor a large nevus flammeus (port-wine stain) with multiple varicose veins and superficial hemangiomas (one of which is pointed by an arrow) below the knee. (ef) Magnetic resonance imaging of lower limbs. Left leg is seen to exhibit subcutaneous overgrowth (e) and right leg multiple vascular malformations (f). (g, h) Enhanced CT scanning of abdomen. Mesenteric lipomatosis is seen on both panels (delineated by yellow arrows) but has reduced substantially in contrast enhancement and bulkiness 2 months after the PIK3CA inhibitor was begun (compare panel h to panel g). Note that the skin lesions had regressed only slightly after 2 months of treatment

Back to article page